ReutersChildren as young as 8 years old should be screened for anxiety and those ages 12 and over for depression, according to new recommendations by the government-backed U.S. Preventive Services Task Force (USPSTF).
© AbbVie Inc. All rights reserved.AbbVie bolstered the company’s neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Sage Therapeutics Inc.’s drug helped improve depressive symptoms after three days in a late-stage study, but investor concerns over how long the treatment’s effect would last sent the drug developer’s shares down 17% on February 16.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
COMPASS Pathways revealed positive topline results from the mental healthcare firm’s Phase IIB clinical trial on the use of COMP360 psilocybin to address treatment-resistant depression (TRD).
Sage Therapeutics and Biogen announced positive and consistent results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder (MDD) and postpartum depression (PPD).
Shares of Axsome Therapeutics were up after the company announced positive long-term results from a Phase III major depressive disorder (MDD) study that sets up potential regulatory approval for AXS-05.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.
Luye Pharma Group submitted a new drug application to the U.S. Food and Drug Administration for LY03005, a new chemical drug for the treatment of major depressive disorder.